Turning Point Therapeutics : Presentation Materials of Turning Point Therapeutics, Inc (Form 8-K)

Fatigue 17 3 12 2 Lipase increased 17 3 17 2 Anaemia 16 5 2 - Amylase increased 15 1 13 1 Nausea 12 1 7 - Vomiting 12 3 4 - Oedema peripheral 11 - 9 - Abdominal pain 10 2 1 -... | October 7, 2021

Related Keywords

New York ,United States ,Australia ,Memorial Sloan Kettering Cancer Center ,Hebron ,Israel General ,Israel ,Texas ,Groningen ,Netherlands ,Madrid ,Spain ,China ,Boston ,Massachusetts ,San Diego ,California ,Melbourne ,Victoria ,Barcelona ,Comunidad Autonoma De Cataluna ,Hwasun Gun ,Cholla Namdo ,South Korea ,Hwasun ,Ch Ungch Ong Namdo ,Germany ,Seoul ,Soult Ukpyolsi ,Heidelberg ,Baden Wüberg ,Republic Of Korea ,D Ross Camidge ,Dipesh Uprety ,Christoph Springfeld ,Enriqueta Felip ,Alexander Drilon ,Victor Moreno ,Denise Trone ,Christina Baik ,Davids Hong ,Athena Countouriotis ,Shanna Stopatschinskaja ,Byoung Chul Cho ,Vamsidhar Velcheti ,Jessicaj Lin ,Mohammad Hirmand ,Young Chul Kim ,Benjamin Besse ,Early Drug Development Service ,Zai Lab ,Yonsei University College Of Medicine ,Heidelberg University Hospital ,Weill Cornell Medical College ,Virtual International Conference On Molecular ,Md Department Of Investigational Cancer Therapeutics ,Nyu Perlmutter Cancer Center ,Seattle Cancer Care Alliance ,University Of Washington School Medicine ,Karmanos Cancer Institute ,University Of Colorado Denver ,University Of Groningen ,Fred Hutchinson Cancer Research Center ,National Center ,Hebron University Hospital ,Peter Maccallum Cancer Center ,Qa Panel Athena Countouriotis ,Drug Administration ,Harvard Medical School ,University Medical Centre Groningen ,Point Therapeutics Inc ,Exchange Commission ,Department Of Medical Oncology ,Chonnam National University Medical School ,Hebron Institute Of Oncology ,Yonsei Cancer Center ,Generation Precision Oncology ,Meeting Exhibit ,Looking Statements ,Introduction Athena Countouriotis ,Chief Medical Officer Elzovantinib ,Data Solid Tumors ,Alterations Mohammad Hirmand ,Panel Athena Countouriotis ,Chief Medical Officer Alexander Drilon ,Memorial Sloan Kettering Cancer Center David ,Investigational Cancer Therapeutics ,Cancer Center Clinical ,Chief Executive Officer ,Therapy Designations ,Solid Tumors Robust Pipeline ,Four Clinical Stage Drug Candidates Developing ,Early Stage Pipeline Elzovantinib ,Breakthrough Therapy ,Kinase Multiple ,Turning Point ,Greater China ,International Conference ,Molecular Targets ,Cancer Therapeutics Poster Presentations Update ,Plenary Presentation ,New Drugs ,Horizoni Repotrectinib ,Chief Medical Officer ,Chul Cho ,Chul Kim ,General Hospital ,Cancer Center ,Yonsei University College ,University Hospital ,Tumor Diseases ,Medical Oncology ,Colorado Denver ,Anschutz Medical Campus ,Maccallum Cancer Center ,Washington School ,National University Medical School ,Hebron Institute ,Cancer Institute ,Sloan Kettering Cancer Center ,Objectives Evaluate ,Dose Finding Expansion Cohorts ,Disposition Data ,Finding All Treated Patients ,Non Evaluable Patients Off Treatment Prior ,Evaluable Scan ,Baseline Measurable Disease ,Baseline Characteristics Data ,Treated Patients ,Baseline Brain Metastasis ,Prior Regimens ,Fall Grade ,Preliminary Safety Summary All Treated Patients ,Adverse Events All Grades ,Grades ,Investigator Assessment Efficacy Outcomes ,Efficacy Evaluable Patients ,Efficacy Outcomes ,Best Overall Response ,Efficacy Evaluable ,Investigator Assessment ,Evaluable Subjects ,Preliminary Efficacy ,Dose Levels ,Recent End ,Turning Point Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Fatigue ,7 , ,2 ,Lipase ,Ncreased ,Anaemia ,6 ,Amylase ,5 ,3 ,Nausea ,Vomiting ,Bedema ,Peripheral ,1 ,Prabdominal ,Rain , 0 , Tptx Us90041t1088 ,